MRNAMRNAModerna, Inc.
$196.79
24h
-4.84%
6 Nov, 03:55

Bearish stance ahead of earnings

Bearish-18.50%

AI Summary

The author takes a short position on Moderna ahead of its earnings report, citing weak historical Q3 performance, strict market expectations, and concerns over growth guidance, expense control, and pipeline progress.

MRNA just hit a new high a few days ago and is releasing earnings tonight. The stock forum is split into two extreme camps: either +20% or -20%. Q3 is their traditional peak revenue period, so market expectations are naturally strict. In the past five Q3 earnings releases, only one resulted in a price increase. This time, the main focus areas are: 1. Whether the full-year growth guidance of at most 10% can hold steady. 2. Expense control and cash burn rate. 3. The pace of the intismeran pipeline (including other tumor types like kidney cancer). I’ve posted the detailed points in my OKX Planet channel. But overall, I’m taking a short position for now.

More Views About MRNA